Australia markets closed

GBS Inc. (GBS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4200+0.0256 (+6.49%)
At close: 04:00PM EDT
0.4200 0.00 (0.00%)
After hours: 04:06PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3944
Open0.4200
Bid0.4200 x 2200
Ask0.4273 x 900
Day's range0.4200 - 0.4400
52-week range0.3600 - 2.8900
Volume17,513
Avg. volume50,617
Market cap6.254M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.5020
Earnings date11 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.50
  • GlobeNewswire

    GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights

    - Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition - - Completed collection and analysis in a study with coincidental sampling of oral fluid and blood to evaluate the time-course of glucose in oral fluids - - Company to host conference call & webcast today at 4:30 p.m. ET - NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasi

  • GlobeNewswire

    GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31

    Company to Host Conference Call & Webcast at 4:30 p.m. ETNEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the fourth quarter and full year ended June 30, 2022, shortly after the NASDAQ market close on Wednesday, August 31. Management will then host a conference call and

  • GlobeNewswire

    GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood

    The trial is single center, prospective study collecting coincident samples of oral fluids and blood to evaluate the time-course of glucose NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced completion of sample collection and analysis of glucose in oral fluid and blood samples from their clinical study at the Diabete